Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qihong Maitong is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Sichuan Yuanda Shuyang Pharmaceutical. It is primarily indicated for the treatment of coronary heart disease (CHD) and stable angina pectoris, specifically for patients presenting with Qi deficiency and blood stasis syndrome. The medication is composed of several herbal extracts, including Astragalus (Huangqi), Panax notoginseng (Sanqi), and Carthamus tinctorius (Honghua). Its pharmacological actions include improving myocardial blood supply, reducing blood viscosity, and inhibiting platelet aggregation, thereby alleviating symptoms such as chest pain, palpitations, and shortness of breath. It is approved for marketing in China and is available in capsule and oral liquid forms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qihong Maitong.